{
  "source": "PA-Med-Nec-Devices.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2163-10\nProgram Prior Authorization/Medical Necessity - Devices\nMedication Alevicyn*, Alevicyn Dermal Spray*, Alevicyn SG*, Aquoral*,\nAtopaderm*, Atopiclair*, Atrapro Antipruritic Hydrogel*, Atrapro\nCP*, Atrapro Dermal Spray*, Caphosol*, Ceracade*, Ceramax*,\nDerpixa*, Dexeryl*, Eletone*, Emulsion SB*, Entty Spray*,\nEpiCeram*, Halucort*, HPR*, HPRPlus*, Hyclodex*, Hylaguard,\nHylatopic Plus*, Hypocyn Dermal Spray*, Iliderm*, KamDoy Rx*,\nKendall Amorphous Hydrogel*, Keragel*, Keragelt*, Kivik*,\nMediHoney*, Microcyn*, Neocera*, Neosalus*, NeutraSal*,\nNutraseb*, Penlen*, Phlag*, PR Cream*, Presera*, Promiseb*,\nPruclair*, Prumyx*, RadiaPlexRx*, SalivaMax*, Strata GRT*,\nSuvicort*, Synerderm*, Tetrix*, Vexasyn*, Zanabin*\nP&T Approval Date 4/2019, 7/2019, 4/2020, 8/2020, 12/2020, 2/2021, 8/2021, 9/2022,\n11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nThe U.S. Food and Drug Administration (FDA) classifies devices as products that are intended\nfor use in the diagnosis, cure, mitigation, treatment, or prevention of a disease that do not\nachieve their purpose through chemical action and are not dependent on metabolism to achieve\ntheir purpose. Devices are typically benefit exclusions. This program only applies when devices\nare covered by the plan.\n2. Coverage Criteriaa:\nA. Initial Therapy\n1. Alevicyn*, Alevicyn SG*, Atopaderm*, Atopiclair*, Atrapro Antipruritic\nHydrogel*, Atrapro CP*, Ceracade*, Ceramax*, Dexeryl*, Eletone*, Emulsion\nSB*, Entty Spray*, EpiCeram*, Halucort*, HPR*, HPRPlus*, Hylaguard,\nHylatopic Plus*, Iliderm*, KamDoy Rx*, Kivik*, Neocera*, Neosalus*,\nNutraseb*, Penlen*, Phlag*, PR Cream*, Presera*,Promiseb*, Pruclair*,\nPrumyx*, Synerderm*, Tetrix*, and Zanabin* will be approved based on all of the\nfollowing criteria:\na. Diagnosis of one of the following:\n(1) atopic dermatitis\n(2) allergic contact dermatitis\n(3) radiation dermatitis\n(4) seborrheic dermatitis\n-AND-\nb. History of fai",
    "on all of the\nfollowing criteria:\na. Diagnosis of one of the following:\n(1) atopic dermatitis\n(2) allergic contact dermatitis\n(3) radiation dermatitis\n(4) seborrheic dermatitis\n-AND-\nb. History of failure or contraindication to two OTC emollients (e.g. Aquaphor,\n© 2024 UnitedHealthcare Services, Inc.\n1\nEucerin, Lubriderm, white petroleum; document name and duration of trial)\n-AND-\nc. History of failure or contraindication to two topical corticosteroids. Document\ntopical corticosteroid name and duration of trial\nAuthorization will be issued for 12 months\n2. Aquoral*, Caphosol*, NeutraSal* and SalivaMax* will be approved based on one\nof the following criteria:\na. Both of the following:\n(1) Diagnosis of xerostomia\n-AND-\n(2) History of failure or contraindication to both of the following:\n(a) saliva stimulants (e.g. sugar-free hard candies or gum)\n-AND-\n(b) Two OTC saliva substitutes (e.g. Biotene, Mouth Kote, Oasis, SalivaSure,\nSalivea) Document name and duration of trial\n-OR-\nb. Both of the following:\n(1) Diagnosis of oral mucositis\n-AND-\n(2) History of failure or contraindication to both of the following:\n(a) topical lidocaine\n(b) salt and sodium bicarbonate rinse\nAuthorization will be issued for 12 months\n3. Alevicyn Dermal Spray*, Atrapro Dermal Spray*, Hyclodex*, Hypocyn Dermal\nSpray* and Microcyn* will be approved based on the following criteria:\na. History of failure or contraindication to two OTC antiseptics (e.g. Betadine,\nDakin’s Solution, Hibiclens). Document name and duration of trial\nAuthorization will be issued for 12 months\n© 2024 UnitedHealthcare Services, Inc.\n2\n4. Derpixa*, Kendall Amorphous Hydrogel*, Keragel*, Keragelt*, MediHoney*,\nRadiaPlexRx*, Strata GRT*, Vexasyn* and Suvicort* will be approved based on\nthe following criteria:\na. History of failure or contraindication to two OTC emollients (e.g. Aquaphor,\nEucerin, Lubriderm, white petroleum; document name and duration of trial)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. The",
    "or contraindication to two OTC emollients (e.g. Aquaphor,\nEucerin, Lubriderm, white petroleum; document name and duration of trial)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. The requested device will be approved based on the following criteria:\na. Documentation of a positive response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Devices are typically excluded from coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. U.S. Food and Drug Administration. Classify Your Medical Device. Last updated 2/7/2020.\nRetrieved from https://www.fda.gov/medical-devices/overview-device-\nregulation/classify-your-medical-device. Accessed October 4, 2024.\n2. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al.\nGuidelines of care for the management of atopic dermatitis: section 2. Management and\ntreatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014\nJul;71(1):116-32.\n3. Fonacier L, Bernstein D, Pacheco K, et al. Atopic dermatitis: A practice parameter update\n2015. J Allergy Clin Immunol 2015;3:S1-S39.\n4. McGuire D, Fulton J, Park J, et al. Systematic review of basic oral care for the management\nof oral mucositis in cancer patients. Support Care Cancer 2013 (31); 3165-3177.\nProgram Prior Authorization/Medical Necessity- Devices\nChange Control\n4/2019 New program.\n7/2019 Aquoral added to program.\n4/2020 Synerderm added to program. Added seborrheic dermatitis as an\napprovable indication.\n© 2024 UnitedHealthcare Servic",
    "- Devices\nChange Control\n4/2019 New program.\n7/2019 Aquoral added to program.\n4/2020 Synerderm added to program. Added seborrheic dermatitis as an\napprovable indication.\n© 2024 UnitedHealthcare Services, Inc.\n3\n8/2020 Halucort added to program.\n12/2020 Caphosol, Hyclodex and Penlen added to program.\n2/2021 Hylaguard added to program.\n8/2021 Alevicyn, Alevicyn Dermal Spray, Alevicyn SG, Atopiclair, Atrapro\nAntipruritic Hydrogel, Atrapro CP, Atrapro Dermal Spray, Carrasyn\nHydrogel, Ceracade, Ceramax, Deripixa, Dexeryl, Emulsion SB, HPR,\nIliderm, Kendall Amorphous Hydrogel, Keragel, Keragelt, Kivik,\nMediHoney, Microcyn, Phlag, PR Cream, Presera, Pruclair, Prumyx,\nRadiaPlexRX, Strata GRT, Suvicort Vexasyn, and Zanabin added to\nprogram.\n9/2022 Hypocyn Dermal Spray added to program.\n11/2023 Annual review. Updated references.\n11/2024 Removed Carrasyn Hydrogel as it is off the market. Increased initial\nauthorization to 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}